2-ТИП ҚАНДЛИ ДИАБЕТДА ГЕМОСТАЗ ТИЗИМИ БУЗИЛИШЛАРИНИНГ МОЛЕКУЛЯР-ГЕНЕТИК БИОМАРКЕРЛАРИ ВА УЛАРНИНГ КЛИНИК АҲАМИЯТИ (Narrative Review)
Keywords:
Калит сўзлар: 2-тип қандли диабет, генетик биомаркерлар, SERPINE1, ADAMTS13, PADI4, F3, ITGB3, тромбоз.Abstract
Аннотация: Мазкур мақолада 2-тип қандли диабет (2-ТҚД) шароитида гемостаз тизими бузилишлари билан боғлиқ асосий молекуляр-генетик биомаркерлар — SERPINE1, ADAMTS13, PADI4, F3 ва ITGB3 генлари ҳамда уларнинг маҳсулотлари тизимли равишда таҳлил қилинган. Ушбу генларнинг полиморфизмлари ва экспрессия даражасининг ўзгариши билан тромботик асоратлар хавфи орасидаги боғлиқлик замонавий адабиётлар асосида кўриб чиқилган. Олинган маълумотлар мазкур генетик биомаркерларнинг келажакда шахсийлаштирилган тиббиёт доирасида хавфни башоратлаш ва даволашни индивидуаллаштиришда қўлланилиши мумкинлигини кўрсатади.
References
1. Festa A., D'Agostino R., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes, 2002.
2. Juhan-Vague I., Alessi M.C., Mavri A., Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. Journal of Thrombosis and Haemostasis, 2003.
3. Eriksson P., Kallin B., van 't Hooft F.M., Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proceedings of the National Academy of Sciences, 1995.
4. Feys H.B., Vandeputte N., Palla R. et al. Inactivation of ADAMTS13 by plasmin as a potential feedback loop in hemostasis. Journal of Thrombosis and Haemostasis, 2010.
5. Lowe G.D. Circulating inflammatory markers and risk of venous thromboembolism: a role for von Willebrand factor and ADAMTS13. British Journal of Haematology, 2008.
6. Skov J., Bladbjerg E.M., Leth Rasmussen L., Antonijevic Z., Jorgensen H. ADAMTS13 and von Willebrand factor in diabetes. Journal of Diabetes and its Complications, 2016.
7. Wang Y., Li M., Stadler S. et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. Journal of Cell Biology, 2009.
8. Menegazzo L., Scattolini V., Cappellari R. et al. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetologica, 2018.
9. Boden G., Vaidyula V.R., Homko C., Cheung P., Rao A.K. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 2007.
10. Samad F., Ruf W. Inflammation, obesity, and thrombosis. Blood, 2013.
11. Bray P.F., Mathias R.A., Faraday N. et al. Heritability of platelet function in families with premature coronary artery disease. Journal of Thrombosis and Haemostasis, 2007.
12. Michelson A.D., Furman M.I., Goldschmidt-Clermont P. et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation, 2000.
13. Ajjan R.A., Ariens R.A. Cardiovascular disease and heritability of the prothrombotic state. Blood Reviews, 2009.
14. Carter A.M. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica, 2012.
